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Abstract
Background: Secretory phospholipase A2 (sPLA2) is a group of enzymes involved in lung tissue inflammation and
surfactant catabolism. sPLA2 plays a role in adults affected by acute lung injury and seems a promising therapeutic
target. Preliminary data allow foreseeing the importance of such enzyme in some critical respiratory diseases in
neonates and infants, as well. Our study aim is to clarify the role of sPLA2 and its modulators in the pathogenesis
and clinical severity of hyaline membrane disease, infection related respiratory failure, meconium aspiration
syndrome and acute respiratory distress syndrome. sPLA2 genes will also be sequenced and possible genetic
involvement will be analysed.
Methods/Design: Multicentre, international, translational study, including several paediatric and neonatal intensive
care units and one coordinating laboratory. Babies affected by the above mentioned conditions will be enrolled:
broncho-alveolar lavage fluid, serum and whole blood will be obtained at definite time-points during the disease
course. Several clinical, respiratory and outcome data will be recorded. Laboratory researchers who perform the
bench part of the study will be blinded to the clinical data.
Discussion: This study, thanks to its multicenter design, will clarify the role(s) of sPLA2 and its pathway in these
diseases: sPLA2 might be the crossroad between inflammation and surfactant dysfunction. This may represent a
crucial target for new anti-inflammatory therapies but also a novel approach to protect surfactant or spare it,
improving alveolar stability, lung mechanics and gas exchange.
Background
Phospholipase A2 biology
Phospholipases A2 are a widely distributed group of
enzymes primarily implicated in the turnover of mem-
brane phospholipids and lipid digestion. They are also
crucial for the inflammation pathways, as they are the
first step for the production of eicosanoids and other
inflammatory mediators [1,2]. Secretory phospholipase
A2 (sPLA2) is the low molecular, well conserved and
secreted form of the enzyme. It is excreted into the
alveoli mainly by macrophages and mast cells [1-3].
sPLA2 has a dual role, as it contributes to the
inflammation pathway and it is also the main enzyme
involved in the catabolism of surfactant [1,2,4] This
complex proteo-lipid mixture is essential for the alveolar
opening and the maintenance of an adequate gas
exchange.
sPLA2 is well known to be involved in lung inflamma-
tion and surfactant degradation based on animal and
human studies in adults [4]. Therefore, it is conceivable
that sPLA2 through either its pro-inflammatory role or
the surfactant catabolism, might be involved in the
pathogenesis of several critical respiratory diseases. Basic
data have shown that both sPLA2 activity and expres-
sion are regulated by many factors including steroids,
Clara Cell Secretory Protein (CCSP), Tumor Necrosis
Factor-a (TNFa), Surfactant protein A (SP-A) and cer-
tain surfactant phospholipids, Interleukine-1 (IL-1) and
some other cytokines [4].
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duction of its modulators may account for increased
surfactant degradation or lung tissue inflammation.
Schematic representation of sPLA2 pathway is presented
in Figure 1: the possible roles of the enzyme in the
pathogenesis of acute respiratory distress syndrome
(ARDS), infant respiratory distress syndrome (iRDS),
broncho-pulmonary dysplasia (BPD), infection related
respiratory failure (IRRF) and meconium aspiration syn-
drome (MAS) are also illustrated. Data about the sPLA2
Figure 1 Possible involvements of sPLA2 pathway in the pathophysiology of critical respiratory diseases in infants. Full lines with
arrows and hatched lines with squares indicate stimulatory and inhibitory actions on the enzyme activity and expression, respectively. Bold
arrows show the direct consequences of the enzymatic activity in different diseases. ARDS: acute respiratory distress syndrome; BPD: broncho-
pulmonary dysplasia; iRDS: infants’ respiratory distress syndrome; IRRF: infection related respiratory failure; MAS: meconium aspiration syndrome;
sPLA2: secretory phospholipase A2; CCSP: clara cell secretory protein; IL-1b: interleukine-1 b; SP-A: surfactant protein-A; TNFa: tumor necrosis
factor-a; MV: mechanical ventilation.
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described in the following paragraphs.
sPLA2 and ARDS
A wide body of literature suggests a role for sPLA2 in
the development of ARDS and acute lung injury (ALI),
its milder form. sPLA2 interferes with the surfactant
activity and so reduces compliance [4-6]. sPLA2 starts a
vicious cycle in which it damages the surfactant; since
some surfactant components have their own inhibitory
effect on sPLA2 activity and expression [7,8], the
sPLA2-induced surfactant damage reduces this inhibi-
tion and thus the enzyme is able to further catabolize
the surfactant phospholipids [4]. Thus, sPLA2 facilitates
the action of other injurious agents against the lung
epithelium, leading to further surfactant damage, alveo-
lar collapse and respiratory impairment [4]. This process
is also linked to the lung tissue inflammation, since
TNFa and some other pro-inflammatory cytokines are
strong sPLA2 inductors throughout the regulation of
NFkB nuclear transcription factor [4,7,8]. Moreover,
sPLA2 itself starts the inflammatory cascade, since it is
the first step in the biochemical pathway leading to the
production of arachidonic acid derivatives [9]. Inflam-
mation may further inactivate surfactant, contributing to
the above-described vicious cycle [4-6]. sPLA2 activity is
raised in broncho-alveolar lavage fluid (BALF) in animal
models of ARDS and in adult patients and this corre-
lates with the clinical severity and mortality [4,5,8,10].
We recently found raised enzyme levels in post-neonatal
ARDS, similarly to the adult findings [11]. Moreover,
respiratory syncytial virus (RSV) infection seems to
cause a more severe ARDS because of the sPLA2 over-
expression, triggered by the RSV itself [12]. Consistently,
transgenic animals defective for the CCSP gene, experi-
ence higher inflammation and mucous production,
when infected by RSV [13].
In animal models, the administration of sPLA2 inhibi-
tors reduced lung inflammation and improved both
compliance and oxygenation, especially if the inhibitor is
administered early during the injury development [8,14].
Similarly, the inhibitor was able to reduce sPLA2 activity
in BALF of patients with iRDS, IRRF, MAS and post-
neonatal ARDS [15].
sPLA2 and iRDS
The importance of surfactant is well known in neonatal
critical care. An inadequate surfactant production is the
pivotal cause of hyaline membrane disease, also called
infant respiratory distress syndrome (iRDS), the most
frequent respiratory disease of preterm infants [16].
Although exogenous surfactant administration is cura-
tive in many preterm infants,l o n g - t e r mr e s p i r a t o r y
sequels are still a significant problem in this population,
with 20% of the surviving preterm babies affected by
BPD [17]. Moreover, the tiniest babies born at the limit
of viability often require multiple surfactant administra-
tions. Many of these very preterm deliveries are asso-
ciated with infections and chorioamnionitis [18]. In
these cases, inflammation lengthens the lung injury,
decreasing the usefulness of exogenous surfactant and
damaging the lung tissue [18]. In such situation, sPLA2
is likely to play a crucial role: we found increased sPLA2
levels in babies with iRDS comparing to normal term
neonates [19]. sPLA2 was found to increase foetal neu-
trophil migration and so to enhance lung tissue inflam-
mation [20]. Babies with higher sPLA2 activity are likely
to be the ones needing repeated surfactant administra-
tions and they are at higher risk for chronic lung
disease.
Some authors recently tried to administer CCSP to
preterm neonates. CCSP is a natural inhibitor of sPLA2
in the lung [21,22]. This drug has been given endotra-
cheally together with surfactant [21] achieving a signifi-
cant reduction in lung tissue inflammation. Similar
results in terms of inflammatory markers and lung func-
tion have been obtained in animal models of iRDS and
MAS [23-25].
Other authors have proposed the same approach with
endotracheally administered budesonide, vehicled by
surfactant [26]. Budesonide inhibits sPLA2 and has been
associated with a decrease in the release of sPLA2-
induced pro-inflammatory cytokines [27]. Surfactant is
the cornerstone of iRDS therapy and the sPLA2 inhibi-
tion could theoretically protect it, reducing the need for
repeated doses and improving the long-term respiratory
outcome.
sPLA2 and IRRF
During sepsis or pneumonia surfactant may be inade-
quately produced and recycled or it may be inactivated
by lung tissue inflammation [28,29]. In these cases sur-
factant therapy is often less useful and does not achieve
the clinical improvement usually seen in iRDS [28,29].
Mortality rate for such condition is still remarkable in
term infants and even higher in preterm babies, who
often experience sepsis or pneumonia as nosocomial
infections acquired in the intensive care units [16].
sPLA2 is raised in BALF of neonates with IRRF [19].
This is consistent with animal and cellular studies show-
ing that bacterial membrane lipopolysaccharide is a
potent inductor of sPLA2 [4]. Nonetheless, no definite
data are available about the role of sPLA2 and its path-
way during IRRF.
sPLA2 and MAS
Pancreatic sPLA2 has been indicated as a main etiologi-
cal agent of MAS, one of the worst form of neonatal
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tion, lung tissue inflammation and airway obstruction
[30-32]. Meconium carries high amounts of sPLA2 and
bile acids that are likely to contribute to lung injury,
increasing sPLA2 activity and causing further surfactant
inactivation [33]. Moreover, not only the pancreatic
sPLA2 but also the pulmonary isoforms of the enzyme
m a yb ei n v o l v e di nt h es y n d r o m e ,[ 3 4 ]a sl u n gs P L A 2
production may be boosted by the meconium-induced
release of pro-inflammatory cytokines [35-37] and
through a specific cross-talk between different enzyme
isoforms [38]. Consistently, we have recently found
raised levels of pulmonary sPLA2 in BALF of patients
affected by MAS when compared to their own meco-
nium and to control babies [39]. MAS still has a mortal-
ity rate of about 50% and sometimes requires invasive
treatments as broncho-alveolar lavage using saline/sur-
factant solutions or extra-corporeal life support [40,41].
sPLA2 is also involved in neonatal bile acids pneumo-
nia, a more rare form of lung injury, [42] in which neo-
natal lungs are challenged with the bile acids coming
from the maternal circulation when the mother is
affected by obstetric cholestasis [43,44]. In this condi-
tion, the neonatal lung may experience a sPLA2 over-
activation [33] due to the bile acids coming from mater-
nal circulation. This may lead to severe respiratory fail-
ure, since bile acids increase the sPLA2 activity enabling
the presentation of the phospholipid substrate to the
catalytic site of the enzyme [45].
sPLA2 genetics and human diseases
It is known that some sPLA2 gene polymorphisms are
associated with chronic obstructive pulmonary or coron-
ary artery disease [46,47]. Given the wide role of sPLA2
in many critical respiratory conditions, an individual
predisposition due to different polymorphisms is likely
to exist. Nevertheless, data about sPLA2 genetics, its
association with respiratory failure and its clinical sever-
ity have not been published.
Methods and design
Study hypothesis and purposes
Available data allow hypothesizing a role for sPLA2 or
its modulators in the pathogenesis, in the clinical sever-
ity and in the development of complications of the
above mentioned types of lung injury. Our aim is to
clarify such role, in order to better understand whether
or not sPLA2 therapeutic inhibition might be a helpful
strategy. To do that, we are planning to:
1. Identify the exact subtype(s) of sPLA2 produced
and secreted into the alveoli during post-neonatal
ARDS-ALI, MAS, iRDS and IRRF. This is important
to know because sPLA2 inhibitors may have a
different specificity for the various enzyme subtypes.
In animal models, distinct sPLA2 subtypes have
been associated to lung dysfunction [1,48-50].
2. Study the main modulators of sPLA2 expression
and activity (TNFa, CCSP, SP-A and IL1). This will
allow identification of possible pathway imbalances
and eventually new therapeutic targets.
3. Clarify what happen to sPLA2 and its pathway
when exogenous surfactant is administered, as it
usually occurs to preterm neonates. This will allow
to understand if there is a link between sPLA2 activ-
ity/overexpression, the repeated need for surfactant
and BPD occurrence.
4. Clarify if there is a genetic predisposition due to
different sPLA2 genes polymorphisms which could
lead to more severe clinical pictures in iRDS, ARDS,
MAS or IRRF or to a long term negative outcome.
Originality of the project
This is the first study aimed at investigating the whole
sPLA2 pathway in the above-described types of lung
injury. To date, no study has addressed the functioning
o ft h ew h o l es P L A 2p a t h w a y ,i n c l u d i n gt h er o l eo f
genetics, pathway modulators and related exogenous
therapies that may affect it. This is essential because
the diseases in which sPLA2 is thought to be impor-
tant are basically different and the enzyme could play
a different role through different subtypes, with differ-
ent influence of its modulators and various response to
the exogenous surfactant administration. Moreover,
gene polymorphisms may play a role affecting the
enzyme activity and so the clinical picture. Further-
more, many respiratory diseases potentially caused or
influenced by sPLA2 are typical of newborn infants (e.
g.: MAS, iRDS) or are present both in adults and in
children, but with different causes and characteristics
(e.g.: ARDS) [51]. Thus, data coming from animal stu-
dies or from adult experience cannot be directly
applied to children and a specific study is warranted.
The data coming from the present project will be cru-
cial for future studies targeted at developing an anti-
sPLA2 therapeutics.
Project management
A multicenter design has been previewed and the pro-
ject will be coordinated at the Laboratory of Clinical
Molecular Biology of the University Hospital “A.
Gemelli“, Catholic University of the Sacred Heart in
Rome. A Study group on Secretory Phospholipase in
Paediatrics (SSPP) has been arranged and project coor-
dinators will be a clinical pathologist/biochemist (Prof.
E. Capoluongo, Head of the Lab) and a paediatric inten-
sivist/neonatologist (Dr. D. De Luca).
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ject:
a. Laboratory group. This consists of biochemists
and biologists experts in several molecular biology
techniques applied to BALF specimens. These inves-
tigators will remain blinded to the clinical data,
which will be known only to the project
coordinators.
b. Clinical group. This will consists of all clinicians
- neonatologists and/or pediatric intensivists - work-
ing in intensive care units (at the University Hospital
“A.Gemelli” or in so called “Collaborating centers”)
where patients’ enrolment, samples and data collec-
tion will be performed.
Clinical investigators will meet a project coordinator
regularly before the beginning of the study. This will
happen by tele-conference or by visiting the collaborat-
ing centre. All investigators will remain in contact dur-
ing the entire project by e-mail and/or tele-conference.
One of the project coordinator will also give a 24h/7d
availability by phone in case of urgent matters.
The project is still open and other intensive care units
are welcomed to participate as collaborating centres.
Interested colleagues should contact the corresponding
author to discuss the study feasibility (please see at the
end of manuscript).
Study phases
To accomplish the study purposes, the work will be sub-
divided in two phases:
1) clinical phase; 2) bench phase.
1) clinical phase
Enrolment The following group of patients will be iden-
tified: iRDS, IRRF, MAS, ARDS-ALI. To be enrolled in a
group babies must fulfil all the following inclusion
criteria:
A. Preterm neonates (gestational age ≤ 37 sett)
with iRDS
C-Reactive protein (CRP) < 10 mg/L or procalcitonin
(PCT) < 0.6 ng/mL in the first 72 hours of life; Chest-X-
rays typical for iRDS; no clinical signs of sepsis; need for
mechanical ventilation.
B. Infants and neonates with IRRF (regardless of
the age)
B1. Early IRRF. Neonates from mother with vaginal
or urine positive cultures. Respiratory distress signs and
CRP > 10 mg/L [52]or PCT > 0.6 ng/mL [53]in the first
72 hours of life; clinical signs of sepsis or blood/BALF
positive culture; need for mechanical ventilation.
B2. Late IRRF. Neonates with respiratory distress signs
b e y o n dt h ef i r s t7 2h o u r so fl i f eo ri n f a n t s ,i r r e s p e c t i v e l y
of the age and CRP > 10 mg/L [52]or PCT > 0.6 ng/mL
[53]; clinical signs of sepsis or blood/BALF positive cul-
ture; need for mechanical ventilation.
C. Neonates with MAS
Neonates with meconium stained and thick amniotic
fluid who required broncho-aspiration following Neona-
tal Resuscitation Program guidelines[54]. Continuous
need for mechanical ventilation at 15 minutes of life.
Chest-X rays typical for MAS.
D. Infants with ARDS-ALI [55]
Infants beyond neonatal age (> 30 days of life) and < 1
year of age under mechanical ventilation and having
PaO2/FiO2 ratio < 200 (ARDS) or < 300 (ALI), chest-X
rays typical for ARDS-ALI, acute onset of the respiratory
distress and no cardiogenic oedema/increase in left atrial
pressure.
A control group has also been previewed, as follows:
E. Infants and neonates without respiratory dis-
eases (NLD: No lung disease)
Patients ventilated for non-pulmonary reasons (e.g.:
anaesthesia, central nervous system diseases), PaO2/FiO2
ratio > 300 or FiO2 = 0.21, negative CRP and PCT, nor-
mal chest-X rays and chest clinical examination.
A careful revision of the clinical characteristics will be
done for each patient at the moment of discharge (or
death). This will be done in each centre to ensure the
appropriateness of diagnosis and internal validity.
Procedures to be performed in the intensive care units
1. Broncho-alveolar lavage.
This procedure will be performed as soon as possible
from the fulfilling of the enrolment criteria. In case of
neonates, broncho-alveolar lavage will be performed in
the following schedule:
￿ PRE-SURFACTANT
￿ POST-SURFACTANT (after at least 12 hours from
the surfactant administration)
￿ PRE-2
nd SURFACTANT (only for babies needing a
second dose)
￿ POST-SURFACTANT (after at least 12 hours from
the 2
nd surfactant administration)
Obviously, for infants receiving just a single surfactant
dose or no surfactant at all, only one or two broncho-
alveolar lavages will be carried out.
This procedure is to be intended a non-bronchoscopic
lavage: it will be performed according to our previously
described and well standardized technique [15] and fol-
lowing the advices of the European Respiratory Society
guidelines [56]. All BALF specimens will be added with
0.9% saline up to 2 mL and a small aliquot of the fluids
will be sent for microbiological culture.
2. 1.5 mL blood drawing in a vial with no anti-coagu-
lant to be centrifuged (see below).
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the blood drawing will be repeated each time. Every
BALF and blood specimens must be obtained within 1
hour from each other.
3. 0.5 mL blood drawing into an EDTA vial to be
immediately stored at 4°C. This blood will be used for
DNA extraction to analyse sPLA2 genes polymorphisms
and will be drawn only once for each baby.
In general, blood drawings will be performed from an
indwelling arterial line or from a central venous line to
avoid haemolysis. Blood without anti-coagulant and
BALF samples will be immediately centrifuged at 3000
rpm for 10 minutes to separate the serum or the super-
natants which will be immediately stored at - 80°C.
Data to be registered in the intensive care units The
following data will be recorded either from the vital
parameters monitors, from the ventilator screen or the
clinical files.
￿ Name and sex
￿ Group of enrolment
￿ Type of ARDS (direct/indirect)
￿ Main identifiable cause of ARDS
￿ Pre-existing respiratory diseases (if any)
￿ Hours of life or hour from the fulfilment of enrol-
ment criteria at which the samples have been
obtained.
￿ Cumulative dose of prenatal steroids (for preterm
neonates)
￿ Doses of steroids received till the enrolment (if
any)
￿ Type of mechanical ventilation provided
￿ Peak inspiratory pressure, positive end-expiratory
pressure, mean airway pressure (Pāw), Expired tidal
volume (pro Kg)
￿ Total respiratory rate and spontaneous respiratory
rate (if any)
￿ Dynamic compliance over ten mechanical breaths
or static compliance using end-expiratory occlusion
(depending on the ventilator)
§
￿ Total respiratory system resistances over ten
mechanical breaths
(If patients are ventilated with high frequency oscilla-
tory ventilation, instead of the above-mentioned para-
meters, Pāw, amplitude and frequency will be recorded.
If a specific flow-sensor [57] is available the tidal volume
delivered during oscillations will also be registered and
used for further calculation [see below]).
￿ Cumulative dose of exogenous surfactant (for
neonates)
￿ FiO2
￿ Oxygen saturation at the right hand
￿ Gestational age/Birth weight or Age in months/
weight
￿ PaCO2 and PaO2
￿ pH
￿ Base excess and Lactate
￿ Mean arterial pressure
￿ Central venous pressure (if available)
￿ Heart rate
￿ Blood urea nitrogen
T h e s ed a t am u s tb er e c o r d e da sc l o s ea sp o s s i b l et o
the broncho-alveolar lavage/blood drawing (max within
1 hour from such procedures). These data will be
recorded in real time in an appropriate electronic data-
base provided by the coordinating centre to each inten-
sive care unit participating in the study.
Moreover, using the above-mentioned data, the fol-
lowing indexes will be calculated:
￿ Oxygenation index (FiO2 ×P āw/PaO2)
￿ PaO2/FiO2 ratio
￿ Ventilatory index (Peak - end expiratory pressure)
× respiratory rate × PaCO2/1000 (if conventional
ventilation is provided)
￿ Alveolar ventilation estimate during high frequency
oscillatory ventilation (DCO2= frequency * (tidal
volume)
2], if a specific flow sensor is available) [58]
Moreover, the following data will be recorded:
￿ Mortality
￿ Intensive care unit length of stay
￿ Duration of invasive ventilation
￿ Duration of oxygen therapy
￿ Any neurological sequel at the discharge
￿ Oxygen requirement after discharge
￿ Diagnosis of chronic lung disease, for preterm neo-
nates, according to the NICHD definition of BPD
[59].
Exclusion criteria Patients with one of the following
characteristics will not be enrolled in any group:
1. Congenital lung malformations of any type
2. Lung or thoracic surgery
3. Lung cancer of any type
4. Congenital complex malformations
5. Patients undergoing extracorporeal life support.
Storage and transfer of data and samples All data will
be anonymously stored in the above described electronic
database and will remain property of the enrolling cen-
tre. At the end of the clinical phase they will be checked
for validity in each centres and then sent in a secured
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mens will be also sent under dry ice to the Coordinating
centre.
2) Bench phase
sPLA2 pathway In serum and BALF supernatants the
following analyses will be performed:
￿ Western blotting for sPLA2-IIA, -V, -X. For this
procedure external (actinin) and internal (recombi-
nant human sPLA2 subtypes, -IIA, -V, -X) controls
will be used and total protein measurements will
also be performed with Bradford’s method [5].
￿ TNFa assay
￿ SP-A assay
￿ IL1 assay
These assays will be performed using specific ELISA/
EIA kits already used to analyse BALF. These meth-
ods have been proven to do not cross-react with
other cytokines and with sPLA2; in previous studies,
coefficients of variation of the standard curve
resulted always ≤ 9% [15,39,60-62].
￿ sPLA2 global activity assay
To do this assay, all samples will be centrifuged (for
10’ at 12000 rpm and then for 3’ at 3500 rpm) through
a membrane-filter with a molecular weight cut-off of 30
kDa (Amicon Ultra centrifugal filter; Millipore, Billera,
MA-USA), to separate the secretory and cytosolic phos-
pholipases (which weight ≈14 kDa and ≈80 kDa, respec-
tively) [39,62,63].
￿ High sensitivity urea nitrogen assay in the BALF
supernatant.
All measurements in BALF will be corrected for the
serum-to-BALF urea ratio, as previously described [64].
sPLA2 genetics sPLA2-IIA [HGNC:9031], -V
[HGNC:9038] and -X [HGNC:9029] genes polymorph-
isms will be studied in the patients’ leukocytes. We
found 15 single nucleotide polymorphisms (SNP) for
these genes. These polymorphisms were searched in the
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), JSNP
(http://snp.ims.u-tokyo.ac.jp), GenBank at the NCBI
(http://www.genbank.com) and Applied Biosystems gen-
otyping databases (http://www.appliedbiosystems.com),
as well as in a previous study linking them to coronary
artery disease [47]. Analysis of genetic polymorphisms
SNP genotyping will be performed by TaqMan allelic
discrimination assay [65]. Polymerase chain reaction will
be performed with specific primers at concentrations of
900 nM. Fluorescence data files from each plate were
analyzed by a specific software. In order to verify the
correct genotype assignment, we will randomly analyse
some of the above screened samples by means of genetic
sequencing (BigDye terminator technique).
All laboratory procedures will be carried out respect-
ing safety regulations and bench investigators will be
blinded to the patients’ group of origin and to their clin-
ical data. To accomplish this blindness, before starting
the bench phase all vials will be re-labelled with a new
code and only the project coordinators will be aware of
the new code.
Statistics and sample size Data will be tested for nor-
mality and then analyzed with parametric or non-para-
metric procedures, as appropriate. Accordingly,
univariate analysis using Student and analysis of var-
iance or Mann-Whitney, Wilcoxon, Kruskal-Wallis and
Friedman tests will be performed. Some laboratory data
will be subjected to correlation analysis with clinical
findings, using Pearson’s, Spearman’so rK e n d a l l ’s tech-
nique, according to data characteristics.
Subsequently, if needed, significant results will be sub-
jected to multiple curve estimation procedure [66] and/
or multivariate analysis according to data characteristics
and the results of the univariate analyses. The genetic
data will be analyzed using c
2 test for the Hardy-Wein-
berg equilibrium of alleles at the individual loci. The
association between genotypes and clinical data will be
tested with c
2-o rF i s h e rt e s ta n dt h e nw i t hl o g i s t i c
regression or analysis of co-variance, as appropriate [67].
All statistical analyses will be performed by the project
coordinators, who have a long experience and formal
training in biostatistics.
Despite a formal sample size calculation is not war-
ranted, based on the available data [5,11,19], we pre-
viewed a convenience sample size, as follows: 50-60
preterm infants affected by iRDS, with at least 20 receiv-
ing a second surfactant dose; for ARDS and IRRF
groups 20 patients will be also convenient, while 10 con-
trol neonates or infants will be considered. These sam-
ple size have been checked for power regarding the
correlation between sPLA2 activity and two selected
clinical variables (using Power and Precision demo rel.
3.2 [68]). Given a-error of 0.05 and a correlation coeffi-
cient (r) ≥ 0.6 and ≥ 0.85 [5,11,19] for the respiratory
compliance and the PaO2/FiO2 ratio, respectively, the
power resulted > 80% in both cases.
The study is supposed to last 12-18 months for the
enrolment phase in each collaborating centre, and 3-6
months for the laboratory phase at the coordinating
centre.
Ethical considerations
The protocol and consent form have been approved by
the Ethical Committee of the University Hospital “A.
Gemelli“ at the Catholic University of the Sacred Heart
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boards in each collaborating centre have also approved
the protocol.
The participation to the study will not change in any
way the routine clinical assistance previewed for every
patient. Furthermore, the participation to the study will
respect all the local Regulations about safety procedures
and the privacy. Informed consent will be given by par-
ents or tutors of each baby, before the enrolment in the
study.
Publication policy
Study results will be presented to each investigator by
teleconference and/or e-mail. If possible a meeting in
occasion of one of the major congresses in the field of
Paediatrics or Critical Care (like the European Society
for Paediatric Research or European Society for Paedia-
tric and Neonatal Intensive Care Congresses) will be
organised. Data will be also presented at these meetings
and the subsequent manuscripts will be circulated
between all investigators for revision. All resulting
manuscripts will be authored by the project coordina-
tors and by the group authorship (SSPP: Study group on
Secretory Phospholipase in Paediatrics).
Discussion
This study, thanks to its multicenter design, will clarify
the role(s) of sPLA2 and its pathway modulators in sev-
eral paediatric and neonatal forms of lung injury. In
fact, enough evidence is available to indicate sPLA2, or
at least some of its subtypes, as a key point in the
pathophysiology of certain critical respiratory diseases.
Inflammation is a complex process and is essential in
many of these conditions: sPLA2 might be the main
crossroad between inflammation and surfactant catabo-
lism. Since this latter is surely an important component
of some clinical situations, sPLA2 is worth to be studied
in its metabolic and genetic issues, trying to correlate
them to the clinical pictures.
Given the peculiarity of such diseases and the relative
rarity of some of them, only a multicentre design will be
able to clarify this field. The purpose is not free from
practical consequences, as several sPLA2 inhibitors are
now available or under advanced development [69].
Many drugs are already used in respiratory critical care
[70] but sPLA2 blockade might represent a new anti-
inflammatory therapy and a novel approach to protect
surfactant or spare it, improving alveolar stability, lung
mechanics and gas exchange.
The establishment of a net of centres involved in clini-
cal research, along with the support of bench investiga-
tors, will help in understanding this field and in building
future randomised interventional studies.
Footnote
§ Compliance measurement depends on the type of
ventilator. Those with the end-expiratory occlusion
w i l lp r o v i d eas t a t i cm e a s u r e ,o t h e r w i s ead y n a m i c
measurement will be done using the hot-wire anem-
ometer flow sensor. In that case, to increase the mea-
surement accuracy, the spontaneous breathing must be
temporarily avoided, gas leaks must be < 5% and stable
respiratory conditions with minimal airway secretions
must be achieved. Conditions and technique for this
measurement have been described in details elsewhere
[15].
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